Clinical Practice Guideline

for Influenza

3 27 2554

(CPG)

3 .. 2554

- 1-3 ( 5 )

- 1 - 5 ( 7 )
- 3
-

-

- () 48 . 3-4

- 90
5-7
- 2009

 70
30

.
-1.

Chest X-ray
1.
<2
60 /
2-12
50 /
1-5
40 /
>5
30 /
24 /
- /
- fine crepitation, bronchial breath sound
- O2 sat. pulse oximeter (SpO2) room air 90%
- Chest X-ray
2.
3.
4. 48 .
5. 90 /
48 .

- (1)
-

-
-

-2.

-
-
-
-
-
- 48 .
-
-
-

2.1 (1)
5
-
- (2)
48 .
-

2.2
-
-
48 .

.
-1.
-
1. : mask
2. : ,
(cohort ward) (cohort building)
-
(www.moph.go.th)

-2.

2.1
- respiratory droplets ( )
1-2 surgical mask
- close contact(6)
- airborne nebulization, respiratory
therapy, bronchoscopy
N95 mask
2.2 1-2
surgical mask

2.3 2-6 .

-3. mask
3.1 mask
- surgical mask
- nebulization
respiratory therapy intubation suction, bronchoscopy N95
mask

. Influenza virus
- Influenza-like illness (ILI)(3)

- nasal swab nasopharyngeal aspirate throat swab tracheal

aspirate
- Influenzavirus RT-PCR
- rapid test

.
-
-
(balanced intake/output)
-

3.2 surgical mask

1.
, -
2.
3.
4. mask
5. mask ,
6. surgical mask 1

3.3 nasopharyngeal swab throat swab
surgical mask goggle ()

. Oseltamivir
-1.
- 48 .
5
- Oseltamivir suspected(4) confirmed cases(5)

1.
2.
3. 48 .
4.
- Oseltamivir 2
5

-2.
-
(pre-exposure) (post-exposure)
-

-3. Oseltamivir
3.1 ( 5 )

75 .

>40 .
75 .
>23 . 40 .
60 .
>15 . 23 .
45 .
<15 . > 1
30 .
( < 1 )
6-11 25 . 3 ././
3-5 20 . 2 ././
1-3 12 . 2 ././

2
2
2
2
2
2
2
2

( 0-1 ) 2 ./.
2
( 0-1 ) 1 ./.
2
3.
1. Creatinine clearance 10-30 ./ 75 .
75 .
2. CAPD : 75 . 30 .
3. Hemodialysis : 75 . 30 .
Hemodialysis
3.2 Oseltamivir
- :

-
-
3.3
- 25
3.4 ()
3.5 Zanamivir (inhaled)
oseltamivir
oseltamivir
1.

oseltamivir
2.
oseltamivir 1-2 oseltamivir 3
3.
oseltamivir
4. oseltamivir

zanamivir 7


1.

1. : (BMI) = (.) / (.)2

30; : / 140

2. 14
3.
-
-
- (/ HIV CD4
350/uL, , )
- ()
-
- 18 ( Reye syndrome)
2.
- 2 65
-

- HIV CD4 350/uL

-

3. Influenza-like illness (lLl)

- 38 /
-
4. Suspected case
lLl

10

5. Confirmed case
RT-PCR
6. Close contact 1-2
mask
mask

1.
()

2.

3.

4.
5.

6.
7.

1.
2.

3.
4.

5.

()

11


6.
2
2 65

www.moph.go.th
. 1422

24

. 02-245-8106, 02-246-0358

02-354-1836

12

1.
2. 6


2 6 - 2 65
3. second
trimester ( 6
)

 Oseltamivir
Oseltamivir Suspension

10 ./.
30 .

Oseltamivir cap
75 .

1.
2. geometric proportion

3.
4. 30 .
5.

10
*
100 .
Sucrose
80
Sodium benzoate
0.1
Water qs to
100 .
Oseltamivir suspension
(.)
< 15 .
> 15 . - 23 .
> 23 . - 40 .
> 40 .

3 . 2
4.5 . 2
6 . 2
1 2

6
45 .
8
60 .
10
75 .

13

Oseltamivir phosphate Roche 2

capsule 75 . (powder for oral suspension) 25 .
12 ./. oseltamivir suspension
capsule
1. Winiarski AP, Infeld MH, Tscherne R, Bachynsky M, Rucki R, Nagano-Mate
K. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir
using commercially available capsules. J Am Pharm Assoc 2003; 47 (6): 747-55).
US Cherry syr Ora-Sweet SF
15 ./. (5 ) 35
(25 ) 5
2. Roche AHFS DRUG INFORMATION 2009
(raw material capsule) sodium benzoate
15 ./. (25 )
3 (5 ) 6

MINISTRY OF PUBLIC HEALTH

,QIOXHQ]DOLNHLOOQHVV!














&;5
























 !












PDVN







6/(












5H\H


+,9&'!X/








V\QGURPH
2VHOWDPLYLU












!






!



!



!












!

















ILQHFUHSLWDWLRQ
EURQFKLDOEUHDWKVRXQG
6S2DW
URRPDLU



&;5







&UHDWLQLQHFOHDUDQFH

&$3'

+HPRGLDO\VLV

+HPRGLDO\VLV